Prolor Biotech Inc., of Nes Ziona, Israel, was issued a notice of allowance for a patent application related to its long-acting reversible-pegylation technology, or RPeg platform, which the company is using to develop therapeutic peptides and small molecules

BioLineRx, of Jerusalem, received two notices of allowance relating to BL-1021, an oral, small molecule for treating neuropathic pain

Lorus Therapeutics Inc., of Toronto, received a patent for lead small-molecule cancer drug LOR-253, covering composition of matter and methods of treating cancer

8,044,201, titled "Stem Cell Cultures," which claims Thiazovivin, a small-molecule Rho-associated kinase inhibitor, as well as compositions and cell culture media comprising Thiazovivin

Lorus Therapeutics Inc., of Toronto, received a notice of allowance for a patent covering composition of matter for lead antimicrobial compound LOR-220 and related small molecules

7,829,576, covering the use of ADL6906 (beloxepin), a small molecule designed to treat pain

Hana Biosciences Inc., of South San Francisco, received a notice of allowance for a pent covering the use of menadione in preventing and treating skin rash in patients taking biologic and small-molecule epidermal growth factor receptor inhibitors

It covers a genus of compounds that includes SF1126, a small-molecule inhibitor of phosphoinositide-3-kinase and mammalian target of rapamycin

It's directed to identifying small molecules that are affected by a drug or toxin using metabolomics and provides a method to evaluate chemical agents for drugs effects and toxicity

Fate Therapeutics Inc., of San Diego, was issued a patent titled "Methods for Reprogramming Somatic Cells," which covers foundational induced pluripotent stem cell technology for identifying agents that enable the reprogramming of human somatic cells, including pluripotency genes, small molecules and biologics

7,452,862, covering conformationally controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists

It covers claims related to the 5-HT4 small-molecule agonist PRX-03140 and to compositions that include PRX-03140 as one of the active ingredients

7,335,679, relating to PX-867, a small molecule in preclinical development

The patent protects the substance RhuDex (and related small molecules) and its pharmaceutical composition

7,244,732, titled "Prodrugs of Heteroaryl Compounds," which covers the use and composition of KP-1461, an oral, small-molecule antiviral designed to work by viral decay acceleration

7,244,732, titled "Prodrugs of Heteroaryl Compounds," which covers the use and composition of KP-1461, an oral, small-molecule antiviral designed to work by viral decay acceleration

The patent claims related to both use and composition of the drug, an oral, small molecule that uses a mechanism, viral decay acceleration, designed to work by increasing the virus' naturally high mutation rate

It covers processes and application of Nanotemplate Engineering, which is used for formulate small molecules, peptides, proteins, plasmid DNA and diagnostic agents

TAFA93 is a small-molecule mTOR inhibitor in development for transplant rejection, autoimmune diseases and oncology